Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
Restored heart function as pluripotent derived cardiac progenitor cells (CPCs) by IPS HEART Advisor Dr. Menasche in his Phase I clinical trial in Paris increased left ventricular ejection fraction (LVEF) from 26% to 38% after three months with no safety issues.
Copyright © 2014 IPS HEART - All Rights Reserved.